Indian Immunologicals Limited
 | |
| Company type | Subsidiary of National Dairy Development Board |
|---|---|
| Industry | Biotechnology |
| Headquarters | Hyderabad, India |
Key people | Dr. K. Anand Kumar (Managing Director) |
| Website | www |
Indian Immunologicals Limited (IIL) is a subsidiary of the National Dairy Development Board. It is based in Hyderabad, Telangana, India.[1] IIL is registered in India as a Public Limited Company under the Companies Act, 1956 (Ministry of Corporate Affairs – MCA Services),[2] It was established in 1982 by the National Dairy Development Board.[3][4]
It is noted for developing veterinary and human vaccines for foot-and-mouth disease, rabies, bacterial vaccines, canine vaccines, hepatitis, measles, MMR and DPT.
IIL is a major supplier of DPT, TT and hepatitis B vaccines to India's large Universal Immunization Programme.[5][6] IIL has three vaccine manufacturing facilities in India. The Gachibowli-Hyderabad facility is engaged in the production of vaccines, while the Karakapatla-Hyderabad facility produces animal health formulations and human vaccines. IIL's facility in Ooty exclusively produces human anti-rabies vaccine, "Abhayrab". Pristine Biologicals Ltd is IIL's subsidiary in New Zealand and is involved in the production of serum used in the manufacture of vaccines.[7] Indian Immunologicals, IIL, on 25 November 2023 launched the measles and rubella vaccine 'Mabella' for children. A live-attenuated MR vaccine developed in partnership with Polyvac Institute of Vietnam was launched as part of the 25th celebrations of the IIL division Human Biologicals Institute (HBI) in Udhagamandalam (Ooty), Tamil Nadu. Indian Immunologicals has introduced first indigenously developed Hepatitis A vaccine, Havisure. The vaccine is available in two formulations: a 1ml dose for adults and a 0.5ml dose for pediatric use.[8][9][10]
Animal Health
[edit]IIL manufactures animal health vaccines and formulations. IIL is the third largest animal health player in the Indian market and the market leader in veterinary biologicals in India. IIL operates one plant that is WHO-GMP and ISO-9001, 14001, 18001 and 27001 certified. IIL also introduced the world's first vaccine against Porcine Cysticercosis –Cysvax. IIL is the only producer of companion animal vaccines in India.[11] Indian Immunologicals Limited advances its fish vaccine development efforts through a collaboration agreement with ICAR-CIBA.[12][13][14]
Human Health
[edit]IIL operates a manufacturing facility in Ooty to manufacture the Vero cell culture rabies vaccine for use in human beings. This plant was set up in 1998 at the specific request of the Government of India in order to phase out use of the older and unsafe sheep brain vaccine (also termed nerve tissue vaccine – NTV) with the modern tissue culture vaccine.
The plant, which commenced commercial production in phases from September 2006, meets a large part of the requirements of the Universal Immunization Programme of the Ministry of Health, Govt of India.[15]
Indian Immunologicals and the Indian Council of Medical Research have signed an agreement for the development of a Zika vaccine.[16] Indian Immunologicals' Dengue Vaccine for Dengue Fever: Prospects for Approval[17][18] Indian Immunologicals Ltd is developing a bi-valent human monoclonal antibody for the treatment of rabies.[19]
Human Biologicals Institute
[edit]IIL established Human Biologicals Institute (HBI) in 1999 to manufacture modern Tissue Culture Anti Rabies Vaccine (TCARV) for human use at Ooty, Tamil Nadu. [20]
International Business
[edit]IIL exports its products to more than 50 countries across the world with a customer focus in Middle East, Asia, Africa, CISR countries and expanding in Central and Latin America.[21]
Coronavirus Vaccine Development
[edit]Immunologicals Limited (IIL) is developing a vaccine for coronavirus in a cross-continental collaboration. It is leading the cross-continental research collaboration in association with the Griffith University of Australia to develop 'live attenuated SARS-CoV-2 Vaccine or COVID-19 vaccine' using the latest codon de-optimization technology.[22] Indian Immunologicals Limited Collaborates on Development of Innovative Needle-free Intranasal COVID-19 Vaccine[23]
See also
[edit]References
[edit]- ^ "Two Central Government PSUs, namely, Indian Immunologicals Ltd (IIL) and BIBCOL have entered into a technology transfer agreement with Bharat Biotech". Press Information Bureau.
- ^ "Indian Immunologicals Limited Information – Indian Immunologicals Limited Company Profile, Indian Immunologicals Limited News on The Economic Times". The Economic Times. Archived from the original on 8 May 2019. Retrieved 24 March 2022.
- ^ "Indian Immunologicals eyes oral vaccine for cervical cancer". The Hindu BusinessLine. 28 June 2010. Retrieved 29 June 2010.
- ^ "Indian Immunologicals Limited". Internet Archive. Archived from the original on 15 April 2012.
- ^ "Indian Immunologicals to launch 4 vaccines in a year". The Economic Times. Retrieved 30 May 2010.
- ^ "Indian manufacturers account for 60% of vaccine supplies made to UNICEF". BioSpectrum. Retrieved 22 August 2017.
- ^ "IIL to invest rs 75 crore to expand Its karkapatla plant in telangana".
- ^ Bureau, The Hindu (19 January 2024). "Indian Immunologicals unveils indigenously developed Hepatitis A vaccine". The Hindu. ISSN 0971-751X. Retrieved 23 December 2024.
{{cite news}}:|last=has generic name (help) - ^ Standard, Business. "IIL launches first indigenously developed Hepatitis A vaccine, 'Havisure'". www.business-standard.com. Archived from the original on 15 March 2024. Retrieved 23 December 2024.
{{cite web}}:|first=has generic name (help) - ^ Bureau, BL Hyderabad (5 September 2024). "IIL rolls out paediatric dose of Hepatitis A vaccine". BusinessLine. Retrieved 23 December 2024.
{{cite web}}:|last=has generic name (help) - ^ ""Indian manufacturers account for 60% of vaccine supplies made to UNICEF"". www.biospectrumasia.com. Retrieved 24 November 2020.
- ^ "Indian Immunologicals Limited, continues its Fish Vaccine development and signs agreement with ICAR-CIBA". APN News. 29 August 2024. Retrieved 23 December 2024.
- ^ Today, Telangana (29 August 2024). "Indian Immunologicals Limited in collaboration with CIBA-ICAR to produce vaccines for fish". Telangana Today. Retrieved 23 December 2024.
- ^ "Indian Immunologicals Limited, continues its Fish Vaccine development and signs agreement with ICAR-CIBA". APN News. 29 August 2024. Retrieved 23 December 2024.
- ^ "Human Biologicals Institute launches Eco Friendly Pack for its Anti Rabies Vaccine 'Abhayrab'". Economic Times HealthWorld.com. Retrieved 8 January 2020.
- ^ Bureau, The Hindu (12 September 2024). "Indian Immunologicals, Indian Council of Medical Reaearch ink pact for Zika vaccine". The Hindu. ISSN 0971-751X. Retrieved 23 December 2024.
{{cite news}}:|last=has generic name (help) - ^ Sujatha, R. (18 March 2024). "Vaccine for dengue may be available commercially by mid-2026". The Hindu. ISSN 0971-751X. Retrieved 23 December 2024.
- ^ kgi-admin (4 October 2023). "Dengue vaccine by Indian Immunologicals for Dengue Fever: Likelihood of Approval". Pharmaceutical Technology. Retrieved 23 December 2024.
- ^ Panda, Manasi (30 September 2022). "Rabies-Monoclonal Antibody - A Perspective". Journal of Communicable Diseases. 54 (03): 22–26. doi:10.24321/0019.5138.202285. ISSN 0019-5138.
- ^ "immunology".
- ^ "International Business | Indian Immunologicals Ltd (IIL)". IIL. Retrieved 24 November 2020.
- ^ "Indian Immunologicals Ltd to develop COVID-19 vaccine in association with Griffith University of Australia". www.timesnownews.com. 23 May 2020. Retrieved 24 November 2020.
- ^ "Indian Immunologicals Limited Collaboratively Develops Game-changing Needle-free COVID-19 Intranasal Vaccine". APN News. 27 August 2024. Retrieved 23 December 2024.
